Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Proactive efforts towards the development of new vaccines and antivirals, and the elimination of bottlenecks in vaccine development, will be essential to containing and eradicating future pandemics.
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
The European Union’s new regulatory framework for medical devices has central implications for the development of new devices, particularly by start-ups.
As an intermediary between cells and scaffolding biomaterials, the extracellular matrix secreted by the cells offers challenges and opportunities for the design and fabrication of engineered tissues.
